#United States #Tampa #Cancer Immunotherapy #Kineta #TuHURA Biosciences

TuHURA Biosciences to Highlight Breakthrough Innovations at BioConnect

TAMPA, Fla., May 13, 2025 – TuHURA Biosciences, Inc., listed on NASDAQ under the symbol HURA, has announced its upcoming participation at the 3rd Annual H.C. Wainwright BioConnect Investor Conference taking place on May 20, 2025. The company specializes in developing cutting-edge technologies within the immune-oncology sector, primarily focused on overcoming various forms of resistance to cancer immunotherapy.

At the forefront of this presentation will be President and CEO Dr. James A. Bianco, who will provide an extensive overview of TuHURA's innovations, particularly its notable IFx-Hu2.0 Phase 3 clinical program. This program aims to address the challenges of primary and acquired resistance that patients with cancer frequently encounter.

Groundbreaking Developments in Cancer Treatment

Among the key highlights will be details of a first-of-its-kind bi-specific immune modulating antibody and peptide conjugates (ADCs, APCs) designed to target Myeloid Derived Suppressor Cells (MDSCs). The inclusion of Kineta, Inc.'s VISTA-inhibiting monoclonal antibody program will also be discussed, showcasing the collaborative efforts aimed at tackling cancer more effectively.

The conference will also serve as a platform for TuHURA’s management to engage in one-on-one discussions with interested members of the investment community, enriching the dialogue around their promising pipeline and strategic vision.

Dr. Bianco emphasizes, “Engagement with investors will provide insight into our unique strategies to combat some of the most aggressive cancers as we strive to deliver therapies that can improve patient outcomes.”

Partnership with Kineta, Inc.

In an important recent development, on December 11, 2024, TuHURA announced a definitive agreement to acquire Kineta, Inc., securing the rights to the novel KVA12123 antibody. This acquisition is designed to enhance TuHURA’s therapeutic arsenal against resistant cancers, merging innovative approaches and expertise from both companies. The merger, expected to conclude in Q2 2025, is subject to meeting specific closing conditions.

Research and Development Initiatives

TuHURA is laying the groundwork for a pivotal study of IFx-Hu2.0, which aims to work in tandem with the FDA-approved Keytruda® (pembrolizumab). This single randomized placebo-controlled Phase 3 trial will focus on advanced or metastatic Merkel Cell Carcinoma, marking a significant step toward regulatory approval.

In light of recent findings, research shows that NPM1 mutations are responsible for driving VISTA expression in acute myeloid leukemia (AML), a phenomenon that facilitates the disease's evasion of immune detection. Building on this insight, TuHURA plans to initiate trials for a menin inhibitor combined with a VISTA-targeting antibody, scheduled to begin in Q3 2025, focused specifically on NPM1 mutated AML cases.

Innovative Technologies in Immune Modulation

The company is also exploring its proprietary Delta Opioid Receptor technology to create novel bi-specific immune modulating ADCs and APCs. These technologies aim to inhibit the immune-suppressing effects of MDSCs within the tumor microenvironment, helping prevent T cell exhaustion and enhancing responses to checkpoint inhibitors and cellular therapies.

Conclusion and Future Outlook

As TuHURA Biosciences prepares for an exciting showcase at the H.C. Wainwright BioConnect Conference, its commitment to transforming the landscape of cancer treatment is evident. The company invites attendees to learn more about its promising approaches and robust pipeline.

For additional updates, visit TuHURA's official website and connect via various social media platforms.

• ---

For further questions or inquiries, reach out to Investor Relations:

• - Monique Kosse
• - Gilmartin Group
• - Email: info@tuhurabio.com

Stay tuned for more updates on TuHURA’s groundbreaking work in cancer immunotherapy, as it paves the way for new treatment options that can improve the lives of patients around the world.